Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dade sells urinalysis tests to Quidel:

This article was originally published in Clinica

Executive Summary

US point-of-care diagnostics company Quidel has completed the acquisition of Dade Behring's Rapignost urine test strip business. "Urinalysis tests are important tools for the physician's overall assessment of patient health and will complement Quidel's existing point-of-care business," said the San Diego, California-based company's vice-chairman, president and CEO, Andre de Bruin. "The addition of this product line is expected to contribute to our near-term revenue and profit growth because it can be included within our existing sales and distribution structure." Financial details were not disclosed.

You may also be interested in...



Artios Pharma Nears Clinic With DNA Repair Response Anticancers

The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.

Fauci Apologizes For UK V US Comments: Not Better, Not Worse, Just Different

The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel